Each year, more than five million people in the United States are infected with human papillomavirus-some strains of which can cause genital warts and cancers-during sex. One of the most common causes of sexually transmitted disease, the virus is highly contagious, and so far, nobody has come up with a way to fight it directly. Doctors can remove the warts with chemicals, lasers or other means, but the virus isn’t affected. Now Quebec-based Origenix Technologies is testing a drug the company believes will combat both the warts and the virus by blocking the microbe’s ability to replicate.
The drug is a specially modified DNA molecule that interferes with one of the genes the virus uses to replicate itself once it infects a human cell. Origenix has completed animal testing of a cream containing the drug, says executive vice president Anthony Payne. The company hopes to begin U.S. clinical trials this summer.
Here’s how a Twitter engineer says it will break in the coming weeks
One insider says the company’s current staffing isn’t able to sustain the platform.
Technology that lets us “speak” to our dead relatives has arrived. Are we ready?
Digital clones of the people we love could forever change how we grieve.
How to befriend a crow
I watched a bunch of crows on TikTok and now I'm trying to connect with some local birds.
Starlink signals can be reverse-engineered to work like GPS—whether SpaceX likes it or not
Elon said no thanks to using his mega-constellation for navigation. Researchers went ahead anyway.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.